Susan O Brien, MD
Medical Oncology · Orange, CANPI 1669577276
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $355,041 of the $414,422 with a category attached, or 85.7%. It is spread thinly across 31 manufacturers, the largest accounting for just 14.9%. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $1395.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$62K
- AstraZeneca$40K
- Pharmacyclics LLC, An Abbvie Company$34K
- Secura Bio, Inc.$29K
- Beigene USA, Inc.$28K
- Pfizer$24K
- plus $197K from 25 others
Across 207 payments — averaging $19,324 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1.4M
- Pfizer$1.3M
- Pharmacyclics LLC, An Abbvie Company$446K
- Acerta Pharma LLC$432K
- Astrazeneca UK Limited$117K
- AbbVie$87K
- plus $133K from 7 others
What the payments were for
- Consulting fees$355,04186%
- Speaking & faculty fees$36,0129%
- Travel & lodging$15,2504%
- Food & beverage$8,1192%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $61,819 |
| AstraZeneca | 29 | $39,865 |
| Pharmacyclics LLC, An Abbvie Company | 27 | $33,881 |
| Secura Bio, Inc. | 3 | $29,350 |
| Beigene USA, Inc. | 24 | $27,820 |
| Pfizer | 21 | $24,360 |
| Hikma Pharmaceuticals USA | 7 | $19,684 |
| Eli Lilly | 9 | $19,274 |
| Bristol Myers Squibb | 8 | $17,086 |
| Gilead | 8 | $13,342 |
| Genentech USA, Inc. | 27 | $12,557 |
| E.r. Squibb & Sons, L.L.C. | 8 | $12,018 |
| Johnson & Johnson | 9 | $11,353 |
| Janssen Global Services, LLC | 10 | $10,567 |
| Verastem, Inc. | 2 | $10,246 |
| Genentech, Inc. | 4 | $9,960 |
| Janssen Research & Development, LLC | 4 | $9,525 |
| GSK | 7 | $8,965 |
| Sumitomo Pharma America, Inc. | 2 | $7,553 |
| Amgen | 1 | $5,841 |
| Janssen Scientific Affairs, LLC | 3 | $5,733 |
| TG Therapeutics, Inc. | 7 | $5,063 |
| Astrazeneca UK Limited | 4 | $4,955 |
| Octapharma USA, Inc. | 1 | $4,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,300 |
| Merck | 1 | $1,500 |
| Epizyme, Inc. | 2 | $1,500 |
| Adaptive Biotechnologies Corporation | 1 | $1,500 |
| Beigene, Ltd. | 1 | $1,300 |
| Beone Medicines USA, Inc. | 4 | $358 |
| Jazz Pharmaceuticals Inc. | 1 | $149 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$414,422 in reported general payments places this provider in the 95th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 48 | $793,725 |
| CalquenceAcalabrutinib Maleate | 45 | $654,015 |
| BosulifBosutinib | 15 | $230,021 |
| VenclextaVenetoclax | 18 | $196,523 |
| Restasis MultidoseCyclosporine | 12 | $8,081 |
| Latanoprost | 11 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $33,881 | $793,72548 claims |
| AstraZenecaCalquence | $39,865 | $654,01545 claims |
| PfizerBosulif | $24,360 | $230,02115 claims |
| AbbVieVenclexta, Restasis Multidose | $61,819 | $204,60330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 379 medical oncology providers in California.
Other medical oncology in Orange
- Farshid DayyaniOrange$1.2M
- Jennifer ValerinOrange$188K
- Sayeh LavasaniOrange$162K
- Victoria VillaflorOrange$91K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Marin XavierSan Diego$919K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.